ATE290879T1 - Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung - Google Patents
Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendungInfo
- Publication number
- ATE290879T1 ATE290879T1 AT00957617T AT00957617T ATE290879T1 AT E290879 T1 ATE290879 T1 AT E290879T1 AT 00957617 T AT00957617 T AT 00957617T AT 00957617 T AT00957617 T AT 00957617T AT E290879 T1 ATE290879 T1 AT E290879T1
- Authority
- AT
- Austria
- Prior art keywords
- muc
- antigen
- antibodies against
- therapeutic antibodies
- therapeutic compositions
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 4
- 102100034256 Mucin-1 Human genes 0.000 title abstract 3
- 108010008707 Mucin-1 Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 239000011230 binding agent Substances 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14949299P | 1999-08-18 | 1999-08-18 | |
| US16471499P | 1999-11-11 | 1999-11-11 | |
| PCT/US2000/022890 WO2001012217A1 (en) | 1999-08-18 | 2000-08-18 | Therapeutic antibody against muc-1 antigen and methods for their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE290879T1 true ATE290879T1 (de) | 2005-04-15 |
Family
ID=26846783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00957617T ATE290879T1 (de) | 1999-08-18 | 2000-08-18 | Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1204423B1 (enExample) |
| JP (2) | JP2003519096A (enExample) |
| AT (1) | ATE290879T1 (enExample) |
| AU (1) | AU782569B2 (enExample) |
| DE (1) | DE60018761T2 (enExample) |
| ES (1) | ES2239032T3 (enExample) |
| WO (1) | WO2001012217A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8038994B2 (en) | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
| WO2002058450A2 (en) | 2000-12-22 | 2002-08-01 | Dana-Faber Cancer Institute, Inc. | Regulation of cell growth by muc1 |
| US20040110846A1 (en) * | 2001-01-30 | 2004-06-10 | Beatrice Leveugle | Perylenequinones for use with immunotherapy agents |
| US6627664B2 (en) * | 2001-01-30 | 2003-09-30 | Altachem Pharma Ltd. | Perylenequinones for use as sonosensitizers |
| US8198400B2 (en) | 2001-03-27 | 2012-06-12 | Oncothyreon, Inc. | Vaccine for modulating between T1 and T2 immune responses |
| CH696871A5 (de) * | 2001-10-26 | 2008-01-15 | Altarex Medical Corp | Verwendung eines chemotherapeutischen Arzneimittels und einer Zusammensetzung, die ein Bindemittel umfasst, zur Herstellung eines Medikamentes zur Krankheitsbehandlung. |
| TR200401834T2 (tr) * | 2002-01-24 | 2005-10-21 | Barnes-Jewish Hospital | İntegrin hedefli görüntüleme etken maddeleri. |
| DE10256900A1 (de) | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
| DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| US8129506B2 (en) | 2003-10-24 | 2012-03-06 | Genzyme Corporation | Modulation of the interaction of MUC1 with MUC1 ligands |
| TWI395591B (zh) | 2004-04-01 | 2013-05-11 | Oncothyreon Inc | 黏液性糖蛋白（ｍｕｃ-１）疫苗 |
| EP1848804B1 (en) * | 2005-01-28 | 2011-10-05 | Ramot at Tel Aviv University, Ltd. | Anti-muc1 alpha beta antibodies |
| ES2526344T3 (es) | 2005-06-28 | 2015-01-09 | Oncothyreon Inc. | Método para el tratamiento de pacientes con una vacuna de glicoproteína mucinosa (MUC-1) |
| AU2006279189B2 (en) | 2005-08-10 | 2011-08-04 | Quest Pharmatech Inc. | Perylenequinone derivatives and uses thereof |
| US8454991B2 (en) | 2006-07-24 | 2013-06-04 | Quest Pharmatech Inc. | Method and device for photodynamic therapy |
| HRP20150307T1 (hr) | 2006-09-10 | 2015-04-24 | Glycotope Gmbh | Upotreba ljudskih stanica podrijetlom iz ljudske leukemije za eksprimiranje protutijela |
| EP1920781B1 (en) | 2006-11-10 | 2015-03-04 | Glycotope GmbH | Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors |
| WO2008097844A2 (en) | 2007-02-02 | 2008-08-14 | Dana -Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins |
| US7972870B2 (en) | 2007-02-02 | 2011-07-05 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3 |
| CN102264765B (zh) | 2008-10-28 | 2016-01-20 | 盐野义制药株式会社 | 抗muc1抗体 |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| EP2565268A4 (en) | 2010-04-28 | 2013-10-09 | Shionogi & Co | NEW MUC1 ANTIBODY |
| KR20140023903A (ko) | 2011-02-24 | 2014-02-27 | 온코타이레온, 인코포레이티드 | 항원보강제를 갖는 muc1 기초 당지질펩티드 백신 |
| BR112014004065A2 (pt) | 2011-08-22 | 2017-03-14 | Glycotope Gmbh | micro-organismos carregando um antígeno de tumor |
| JP2017009287A (ja) * | 2013-11-11 | 2017-01-12 | 東ソー株式会社 | 前立腺癌と前立腺肥大症との識別方法 |
| AU2015254257B2 (en) | 2014-04-28 | 2021-02-25 | Medicinal Chemistry Pharmaceuticals, Co., Ltd. | Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof |
| CA3050039A1 (en) * | 2017-01-27 | 2018-08-02 | Glycotope Gmbh | Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor |
| BR112020023373A2 (pt) | 2018-05-18 | 2021-02-09 | Daiichi Sankyo Company, Limited | conjugado, composição, e, uso de um conjugado ou de uma composição |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3698370B2 (ja) * | 1992-04-13 | 2005-09-21 | ダナ−ファーバー キャンサー インスティチュート インク | 癌腫抗原用抗体 |
| JPH08505119A (ja) * | 1992-07-06 | 1996-06-04 | バイオミラ、インコーポレーテッド | 接合目的のためのタンパク質の光活性化 |
| AU5615594A (en) * | 1992-11-13 | 1994-06-08 | Cancer Research Fund Of Contra Costa | Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods |
| DE19534630A1 (de) * | 1995-09-18 | 1997-03-20 | Max Delbrueck Centrum | Monoklonale Antikörper gegen epitheliales Muzin (MUC1) |
| NZ505174A (en) * | 1996-05-15 | 2002-03-01 | Altarex Inc | Cancer antigens CA125 (multiple epitote) recognised by OC125, M11, B43.13, B27.1, where B43.13 is used as a binding agent to elicit host immune response as a vaccination method against cancer |
| WO1998033470A2 (en) * | 1997-01-10 | 1998-08-06 | Altarex Corp. | Substituted perylenequinones for use in photodynamic therapy |
| JP2002502621A (ja) * | 1998-02-13 | 2002-01-29 | バステルト・ギュンター | 乳腫瘍を伴うムチンに対する特異性のある抗体、その生産方法及び使用方法 |
-
2000
- 2000-08-18 JP JP2001516562A patent/JP2003519096A/ja not_active Withdrawn
- 2000-08-18 AT AT00957617T patent/ATE290879T1/de active IP Right Revival
- 2000-08-18 EP EP00957617A patent/EP1204423B1/en not_active Expired - Lifetime
- 2000-08-18 DE DE60018761T patent/DE60018761T2/de not_active Expired - Lifetime
- 2000-08-18 AU AU69211/00A patent/AU782569B2/en not_active Ceased
- 2000-08-18 WO PCT/US2000/022890 patent/WO2001012217A1/en not_active Ceased
- 2000-08-18 ES ES00957617T patent/ES2239032T3/es not_active Expired - Lifetime
-
2011
- 2011-09-06 JP JP2011193430A patent/JP2012046518A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001012217A9 (en) | 2002-06-27 |
| JP2012046518A (ja) | 2012-03-08 |
| EP1204423B1 (en) | 2005-03-16 |
| DE60018761D1 (de) | 2005-04-21 |
| DE60018761T2 (de) | 2006-02-02 |
| ES2239032T3 (es) | 2005-09-16 |
| EP1204423A1 (en) | 2002-05-15 |
| AU782569B2 (en) | 2005-08-11 |
| AU6921100A (en) | 2001-03-13 |
| WO2001012217A1 (en) | 2001-02-22 |
| JP2003519096A (ja) | 2003-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE290879T1 (de) | Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung | |
| CY1120070T1 (el) | Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους | |
| DK1383785T3 (da) | Rekombinant tumorspecifikt antistof og anvendelse deraf | |
| EP1572087A4 (en) | ANTIBODY TO CANCERANT TMEFF2 AND ITS APPLICATIONS | |
| TR200000756T2 (tr) | Davranış bozukluğu tedavisi. | |
| AR035977A1 (es) | Inmunoconjugados de anticuerpos cd44 citotoxicos. | |
| IL139700A (en) | Immunotherapeutic composition for the treatment of prostate cancer | |
| DE69531679D1 (de) | Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper | |
| IL200404A (en) | Couplings of 191p4d12 (b) protein-binding antibodies and their use in the treatment of cancer | |
| EP1355563A4 (en) | METHODS OF PREVENTING AND TREATING CANCER WITH ANTI-C3B (I) ANTIBODIES | |
| DE69433406D1 (de) | Antikörper gegen cd40 | |
| DE69724428D1 (de) | Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren | |
| WO2003072736A3 (en) | Reagents and treatment methods for autoimmune diseases | |
| DE69703121D1 (de) | Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit | |
| WO2004010947A3 (en) | Humanized antibodies against human 4-1bb | |
| DK1479696T3 (da) | Humant monoklonalt antistof, der binder til Ep-CAM, og dets anvendelse ved cancerterapi | |
| BR9612619A (pt) | Método e composição para reconformar antígenos multiepitópicos para iniciar uma resposta imunológica | |
| EP1581096A4 (en) | ANTIGEN PIPA AND BINDING ANTIBODIES THEREOF | |
| TW200517124A (en) | Fully human antibodies against human 4-1BB | |
| WO2000074729A3 (en) | Alpha or beta emitters to fragments in radioimmunotherapy | |
| AU2002354806A1 (en) | Parathyroid hormone antibodies and related methods | |
| TR200103432T2 (tr) | Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı. | |
| GB0102145D0 (en) | Substances | |
| AU2003215381A8 (en) | Egfrviii specific monoclonal antibody and egfrviii ribozymes and use to detect, treat or prevent egfrviii associated cancer | |
| AU641736B2 (en) | Delivery of agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1204423 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee | ||
| EEWE | Authorization for restitution |